<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00751530</url>
  </required_header>
  <id_info>
    <org_study_id>07-11</org_study_id>
    <nct_id>NCT00751530</nct_id>
  </id_info>
  <brief_title>BRAVO: Background Regimen of Raltegravir on Virologic Outcome</brief_title>
  <acronym>BRAVO</acronym>
  <official_title>Outcomes of Early Raltegravir Experience: Comparison of Virologic Response in Regimens Not Containing a Protease Inhibitor in the Antiretroviral Background Regimen Versus a Protease Inhibitor in the Background Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Community Research Initiative of New England</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Community Research Initiative of New England</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a retrospective chart review of participants in raltegravir expanded access program
      and will compare virologic response in regimens not containing a protease inhibitor in the
      antiretroviral background regimen to regimens containing a protease inhibitor in the
      background regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      EAP charts from patients at the study sites who meet the inclusion criteria will be reviewed
      and data abstracted. A comparison of the response to treatment by viral load measurement with
      raltegravir will be compared in patients whose regimens contained a protease inhibitor (PI)
      with those that did not contain a PI. Other endpoints will also be assessed including percent
      of patients with viral loads less than 400 copies/ml, less than 50 copies/ ml, CD4 cell
      changes, consequences of failure of raltegravir and use of predictive parameters such as GSS
      and PSS.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2008</start_date>
  <completion_date type="Actual">June 15, 2009</completion_date>
  <primary_completion_date type="Actual">June 15, 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Viral Load &lt; 400 Copies /mL at Week 12.</measure>
    <time_frame>12 Weeks</time_frame>
    <description>The HIV RNA (viral load) was measured using standard of care testing via local laboratories.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Viral Load &lt; 75 Copies/ mL at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>The HIV RNA (viral load) was measured using standard of care testing via local laboratories.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 Cell Changes Among Participants in PI vs Non-PI Group</measure>
    <time_frame>baseline to 24 Weeks</time_frame>
    <description>CD4 cell counts were measured using standard of care testing via local laboratories.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Genotypic Sensitivity Score (GSS). The Minimal Value Was 0 and the Maximum Values Was 5.4. (0 = Minimal to no Activity in Regimen and 5.4 = High to Maximal Activity in Regimen)</measure>
    <time_frame>Baseline</time_frame>
    <description>The baseline GSS is calculated by the sum of resistance scores for each drug in the regimen. For each drug in the regimen a resistance score of 0, 0.5 or 1 was assigned for high, low or no levels of resistance, respectfully. The resistance assignment was based on either the Stanford database interpretation or presence of primary IAS mutation levels of resistance. Inclusion of maraviroc or new use of enfuvirtide in the regimen was scored a 1.0. The sum of the scores of the active drugs, not including raltegravir, constituted the baseline GSS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Using Etravirine in Background Regimen</measure>
    <time_frame>Background regimen (no specific time frame)</time_frame>
    <description>These results report the percent of participants using Etravirine in the background regimen.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">442</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Protease Inhibitor Group</arm_group_label>
    <description>Subjects who required a protease inhibitor in their new ART regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-protease Inhibitor</arm_group_label>
    <description>Subjects who did not take a protease inhibitor in their regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>raltegravir</intervention_name>
    <description>New combination ART incorporating raltegravir with other ARVs.</description>
    <arm_group_label>Protease Inhibitor Group</arm_group_label>
    <arm_group_label>Non-protease Inhibitor</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population consists of individuals who were previously enrolled in raltegravir
        expanded access program(EAP) and completed at least 8 weeks of treatment with raltegravir,
        whose chart from EAP program is available for review, and whose resistance testing prior to
        initiation of raltegravir is available.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients previously enrolled in the MK 0518 EAP are eligible

          -  Patients not enrolled in the MK 0518 EAP (or other Raltegravir protocols) but who meet
             the specific EAP protocol entry criteria are eligible:

               -  Age &gt;= 16 years

               -  Limited or no treatment options due to resistance or intolerance to multiple
                  antiretroviral regimens, documented resistance to at least one drug in each of
                  the 3 classes of oral ARTs (NRTI, NNRTI, PI) by genotype or phenotype testing,
                  intolerance defined as having had a clinically significant adverse event which in
                  the opinion of the clinician provides a contraindication to the use of any drug
                  in that class iii. Patient did not achieve virologic suppression on ART regimen
                  prior to receipt of raltegravir iv. Patient was clinically stable at time of
                  initiation of raltegravir, eg. clinical status and all chronic medications
                  (except ARTs) unchanged for &gt;= 2 weeks prior to raltegravir receipt.

          -  Patient received raltegravir for at least 8 weeks

          -  Baseline and week 8 or later HIV viral load done and available for review

          -  Resistance test (either genotypic or phenotypic test) available prior to receipt of
             raltegravir

        Exclusion Criteria:

          -  Patient did not receive approved raltegravir dose of 400 mg BID for at least 8 weeks.

          -  Patient chart not available for review.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Skiest, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Community Research Initiative</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Light Source Medical</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>900036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Healthcare Foundation</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synergy Hematology and Oncology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quest Clinical Research</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connecticut Health Care Group</name>
      <address>
        <city>Glastonbury</city>
        <state>Connecticut</state>
        <zip>06033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dupont Circle Physicians Group</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital Medical Associates PC</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Immunology Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruth M. Rothstein CORE Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Research Initiative</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Research Initiative - West</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Diseases and HIV Medicine Immunodeficiency Clinic</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bellman, MD</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mounzer, MD</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Nicholaos C. Bellos &amp; Associates</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2008</study_first_submitted>
  <study_first_submitted_qc>September 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2008</study_first_posted>
  <results_first_submitted>July 22, 2010</results_first_submitted>
  <results_first_submitted_qc>May 18, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 17, 2011</results_first_posted>
  <last_update_submitted>June 13, 2017</last_update_submitted>
  <last_update_submitted_qc>June 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>AIDS</keyword>
  <keyword>raltegravir</keyword>
  <keyword>BRAVO</keyword>
  <keyword>protease inhibitor</keyword>
  <keyword>treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Protease Inhibitors</mesh_term>
    <mesh_term>HIV Protease Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Protease Inhibitor Group</title>
          <description>Subjects who required a protease inhibitor in their new ART regimen</description>
        </group>
        <group group_id="P2">
          <title>Non-protease Inhibitor</title>
          <description>Subjects who did not take a protease inhibitor in their regimen</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="332"/>
                <participants group_id="P2" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="332"/>
                <participants group_id="P2" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Protease Inhibitor Group</title>
          <description>Subjects who required a protease inhibitor in their new ART regimen</description>
        </group>
        <group group_id="B2">
          <title>Non-protease Inhibitor</title>
          <description>Subjects who did not take a protease inhibitor in their regimen</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="254"/>
            <count group_id="B2" value="86"/>
            <count group_id="B3" value="340"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="247"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="329"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="229"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="254"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Viral Load &lt; 75 Copies/ mL at Week 12</title>
        <description>The HIV RNA (viral load) was measured using standard of care testing via local laboratories.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Protease Inhibitor Group</title>
            <description>Subjects who required a protease inhibitor in their new ART regimen</description>
          </group>
          <group group_id="O2">
            <title>Non-protease Inhibitor</title>
            <description>Subjects who did not take a protease inhibitor in their regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Viral Load &lt; 75 Copies/ mL at Week 12</title>
          <description>The HIV RNA (viral load) was measured using standard of care testing via local laboratories.</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="254"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD4 Cell Changes Among Participants in PI vs Non-PI Group</title>
        <description>CD4 cell counts were measured using standard of care testing via local laboratories.</description>
        <time_frame>baseline to 24 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Protease Inhibitor Group</title>
            <description>Subjects who required a protease inhibitor in their new ART regimen</description>
          </group>
          <group group_id="O2">
            <title>Non-protease Inhibitor</title>
            <description>Subjects who did not take a protease inhibitor in their regimen</description>
          </group>
        </group_list>
        <measure>
          <title>CD4 Cell Changes Among Participants in PI vs Non-PI Group</title>
          <description>CD4 cell counts were measured using standard of care testing via local laboratories.</description>
          <units>cells/mm3</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-96.6" lower_limit="-310" upper_limit="768"/>
                    <measurement group_id="O2" value="-134.8" lower_limit="-385" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Genotypic Sensitivity Score (GSS). The Minimal Value Was 0 and the Maximum Values Was 5.4. (0 = Minimal to no Activity in Regimen and 5.4 = High to Maximal Activity in Regimen)</title>
        <description>The baseline GSS is calculated by the sum of resistance scores for each drug in the regimen. For each drug in the regimen a resistance score of 0, 0.5 or 1 was assigned for high, low or no levels of resistance, respectfully. The resistance assignment was based on either the Stanford database interpretation or presence of primary IAS mutation levels of resistance. Inclusion of maraviroc or new use of enfuvirtide in the regimen was scored a 1.0. The sum of the scores of the active drugs, not including raltegravir, constituted the baseline GSS.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Protease Inhibitor Group</title>
            <description>Subjects who required a protease inhibitor in their new ART regimen</description>
          </group>
          <group group_id="O2">
            <title>Non-protease Inhibitor</title>
            <description>Subjects who did not take a protease inhibitor in their regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Genotypic Sensitivity Score (GSS). The Minimal Value Was 0 and the Maximum Values Was 5.4. (0 = Minimal to no Activity in Regimen and 5.4 = High to Maximal Activity in Regimen)</title>
          <description>The baseline GSS is calculated by the sum of resistance scores for each drug in the regimen. For each drug in the regimen a resistance score of 0, 0.5 or 1 was assigned for high, low or no levels of resistance, respectfully. The resistance assignment was based on either the Stanford database interpretation or presence of primary IAS mutation levels of resistance. Inclusion of maraviroc or new use of enfuvirtide in the regimen was scored a 1.0. The sum of the scores of the active drugs, not including raltegravir, constituted the baseline GSS.</description>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="254"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="0" upper_limit="5.4"/>
                    <measurement group_id="O2" value="1.7" lower_limit="0" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Viral Load &lt; 400 Copies /mL at Week 12.</title>
        <description>The HIV RNA (viral load) was measured using standard of care testing via local laboratories.</description>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Protease Inhibitor Group</title>
            <description>Subjects who required a protease inhibitor in their new ART regimen</description>
          </group>
          <group group_id="O2">
            <title>Non-protease Inhibitor</title>
            <description>Subjects who did not take a protease inhibitor in their regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Viral Load &lt; 400 Copies /mL at Week 12.</title>
          <description>The HIV RNA (viral load) was measured using standard of care testing via local laboratories.</description>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="254"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Using Etravirine in Background Regimen</title>
        <description>These results report the percent of participants using Etravirine in the background regimen.</description>
        <time_frame>Background regimen (no specific time frame)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Protease Inhibitor Group</title>
            <description>Subjects who required a protease inhibitor in their new ART regimen</description>
          </group>
          <group group_id="O2">
            <title>Non-protease Inhibitor</title>
            <description>Subjects who did not take a protease inhibitor in their regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Using Etravirine in Background Regimen</title>
          <description>These results report the percent of participants using Etravirine in the background regimen.</description>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Protease Inhibitor Group</title>
          <description>Subjects who required a protease inhibitor in their new ART regimen</description>
        </group>
        <group group_id="E2">
          <title>Non-protease Inhibitor</title>
          <description>Subjects who did not take a protease inhibitor in their regimen</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Site Investigators (PIs) agree not to individually publish the results of the study. They may participate in a joint publication of the study results with the sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Project Manager</name_or_title>
      <organization>Community Research Initiative</organization>
      <phone>617 502 1700</phone>
      <email>pmacht@crine.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

